

# SFPT 2023

LIMOGES | Faculté de Droit et des Sciences Économiques | 12 > 14 juin



## PROGRAMME

Congrès de la Société Française de Pharmacologie et de Thérapeutique



Société Française de  
Pharmacologie et de Thérapeutique



# Mot de Bienvenue

Chers collègues et ami(e)s,

Notre congrès annuel de la SFPT se déroulera à Limoges, capitale de la province historique du Limousin, où culture, gastronomie et patrimoine s'entremêlent dans un écrin de paysages verdoyants et vallonnés...

Mais, au-delà de cette séduisante invitation aux accents de promotion touristique, vous viendrez avant tout pour l'excellent programme préparé par le conseil scientifique avec l'appui du comité local. Car, cette année encore, notre congrès vous promet des sessions pharmacologiques et thérapeutiques passionnantes. Notre premier objectif est d'apporter des mises au point didactiques et actualisées, collant à nos exigences professionnelles à l'hôpital, la faculté ou au laboratoire. Mais nous élargirons également nos horizons en privilégiant les sessions translationnelles et couvrant l'étendue de nos champs disciplinaires, de la molécule à l'Homme.

Ainsi, les conférences plénières seront captivantes, les communications brèves seront motivantes, les tables rondes seront stimulantes, les symposiums industriels seront pointus, les réunions professionnelles seront confraternelles et les pauses-café seront cordiales. Quant à la soirée de gala, tout un programme...

A très bientôt, à Limoges !

**Luc Zimmer**

Président du conseil scientifique de la SFPT



SEPT 2023

## Sociétés & Comités

### CONSEIL D'ADMINISTRATION

**Dominique DEPLANQUE (Président)**

**Pierre-François DEQUIN (Vice-Président)**

**Frédéric LIBERT (Trésorier)**

**Nicolas PICARD (Secrétaire Général)**

Laurent BERTOLETTI

Pascal BOUSQUET

Jean-Luc CRACOWSKI

Céline DEMOUGEOT

Sébastien FAURE

Véronique LAMARQUE-GARNIER

Mathieu MOLIMARD

Jean-Louis MONTASTRUC

Stéphane MOULY

Catherine OIRY-CUQ

Antoine PARIENTE

Luc ZIMMER (Président CS)

### CONSEIL SCIENTIFIQUE

**Luc ZIMMER (Président)**

**Matthieu ROUSTIT (Vice-Président)**

**Caroline VICTORRI-VIGNEAU (Vice-Présidente)**

Mathieu CHARVERIAT

Dominique DEPLANQUE (Président CA)

Charles DOLLADILLE

Véronique LEBLAIS

Jean-Christophe LEGA

Florian LEMAITRE

Florian NAUDET

Françoise STANKE-LABESQUE

### COMITÉ LOCAL D'ORGANISATION

Jean-Baptiste WOILLARD

Philippe BERTIN

Pascale VERGNE-SALLE

Pierre MARQUET

Caroline MONCHAUD

Marie-Laure LAROCHE

Nicolas PICARD

Marc LABRIFFE

Roland LAWSON

Hélène GENIAUX

Franck SAINT-MARCOUX



**LUNDI 12 JUIN**

10h00 - 18h00

Hall d'accueil

Accueil des participants

10h30 - 16h00

Amphi 400 A

Journée des CIC

09h30 - 10h30 Accueil café

Ouverture : Bruno François

Président de séance : Dominique Deplanque

10h30 CIC : Vision des institutions

Pr Karim Asehnoune, Président-administrateur du CNCR

Marie Daudé, Directrice générale de l'offre de soins

Pr Didier Samuel, Président-Directeur Général de l'Inserm

11h00 Table ronde : Modèle rénové des CIC

Dominique Deplanque, Coordonnateur du réseau national des CIC

Albane Miron de l'Espinay, Bureau PF4 DGOS

Hélène Esperou, Responsable du PRC, Inserm

Erik Domain/ Pascale Mocaer, Représentants de la Conférence des DG de CHU

Olivier Rascol, Coordinateur F-crin

Michèle Cottier, Responsable pôle "Santé", Hcéres

12h30 - 13h30 Pause déjeuner

Présidente de séance : Claire Thalamas

13h30 Présentation de l'appel à projets Méthodologie des ESSais cliniques Innovants,

Dispositifs, Outils et Recherches Exploitant les données de santé et biobanques

"MESSIDORE" 2022

Arnaud De Guerra, Directeur adjoint Institut Thématique Santé Publique, Inserm

14h00 Projets

Genèse de la cohorte "Histoplasmosse" et coopération internationale

Mathieu Nacher, CIC 1424, Cayenne

L'évaluation des logiciels et de l'IA

Frédéric Barbot, CIC 1429, Garches, réseau F-crin TECH4HEALTH

Territoire du Limousin : Focus sur les études en médecine générale et du réseau GénéraLIM

Elodie Pfender, CIC 1435, Limoges

La dénervation rénale par voie endovasculaire dans le traitement de l'hypertension artérielle:

de la preuve de concept à la mise à disposition de la procédure

Michel Azizi, CIC 1418, Hôpital Européen Georges-Pompidou

Immunothérapies intra-tumorales : utiliser la tumeur comme son propre vaccin

Aurélien Marabelle, CIC 1428, Institut Gustave Roussy

16h00 Clôture

10h30 - 12h00

Amphi C. Lombois  
(A600)

Groupe Communication

10h30 - 12h00

Salle 309

Groupe STP-PT

10h30 - 12h00

Groupe Pharmaco-épidémiologie

10h30 - 12h00

Amphi 400 B

Groupe REVISE

10h30 - 12h00

Amphi 400 C

**Réseau Avenir : à la découverte de la zététique, conférence de Thomas Durand ouverte à tous!**

La zététique. Si vous ne savez pas ce que c'est, si vous souhaitez en apprendre plus sur cet "art du doute", si vous souhaitez mieux questionner vos informations, le groupe AVENIR vous donne rendez-vous avec Thomas Durand, youtubeur présentant la chaîne "La Tronche en Biais", pour parler de ce sujet. Ouvert à tous, venez nombreux!

11h30 - 12h30

Hall d'accueil

Déjeuner &amp; visite des stands

12h30 - 12h40

Amphi C. Lombois (A600)

Ouverture du congrès

Dominique DEPLANQUE (Président de la SFPT)  
Luc ZIMMER (Président du Conseil Scientifique)  
Pierre MARQUET, Jean-Baptiste WOILLARD et Pascale VERGNE-SALLE (Comité Local d'Organisation)

12h40 - 13h25

Amphi C. Lombois (A600)

Conférence inaugurale

Conférence invitée  
If God Doesn't Play Dice, Should Doctors? - David HEALY (UK)

13h30 - 15h00

Amphi 400 C

Session translationnelle #1 : Pharmacologie cardiovasculaire

Modérateurs : Jérémy BELLIEEN (Rouen), Jean-Luc CRACOWSKI (Grenoble)

Conférence invitée  
13h30 Le rôle de la famille TGF- $\beta$  et de ses dysfonctionnements dans le remaniement vasculaire associé à l'Hypertension Artérielle Pulmonaire - Christophe GUIGNABERT (Paris)

Communications libres

14h00 - CO-001 - Chronic endothelial dopamine receptor stimulation improves endothelial function and hemodynamics in autosomal dominant polycystic kidney disease (IMPROVE-PKD)

A. Dumont

14h10 - CO-002 - Evaluating the Association Between non High-Density Lipoprotein Cholesterol Reduction and Clinical Efficacy of Statins

L. Liaigre

14h20 - CO-003 - Acute vasopressin neutralization improves cardiac function in rats with chronic heart failure	Y. Stephan
14h30 - CO-004 - Administration of etifoxine, a dual TSPO and GABA-A ligand, worsens myocardial ischemia-reperfusion injuries.	S. Leick
14h40 - CO-005 - Vasodilatory and hypotensive effects of a quercetin derivative: quercetin 3-methyl ether 3'-O-β-xylopyranoside	P. Totoson
14h50 - CO-006 - The estimation of clearance of iohexol: a generic pharmacokinetic model for kidney transplant patients and living donors	A. Drague

**13h30 - 15h00**

**Amphi 400 B**

### Session translationnelle #2 : Oncologie et hématologie

Modérateurs : Fabien DESPAS (Toulouse), Théodora BEJAN-ANGOULVANT (Tours)

Conférence invitée

13h30 Approches translationnelles en onco-pharmacologie : l'exemple de la myocardite immuno-induite - Charles DOLLADILLE (Caen)

Communications libres

14h00 - CO-007 - Real-world treatment patterns in French metastatic castration-resistant prostate cancer patients under abiraterone or enzalutamide.	L.-M. Scailteux
14h10 - CO-008 - JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms	N. Maslah
14h20 - CO-009 - Discrepancies between DPD phenotype and genotype: what are the explanatory factors?	C. Arrivé
14h30 - CO-010 - Next Generation Sequencing versus multiplex-genotyping for preemptive pharmacogenetics in oncology	D. Chastagner
14h40 - CO-011 - How many patients with cancer associated thrombosis, would be eligible for a randomized controlled trial evaluating a direct oral anticoagulant in routine clinical practice?	G. Poenou
14h50 - CO-012 - Meta-analysis of phase I dose-finding studies: application for protein kinase inhibitors developed in oncology	L. Caquelin

**13h30 - 15h00**

**Amphi C. Lombois (A600)**

### Pharmaco-épidémiologie

Modératrice : Marie-Laure LAROCHE (Limoges), Jean-Luc FAILLIE (Montpellier)

Conférence invitée

13h30 Déprescription médicamenteuse - Lucas MORIN (Karolinska - Suède)

Communications libres

14h00 - CO-013 - Bleeding risk with concurrent use of anticoagulants and ibrutinib: a population-based nested case-control study	M. Allouchery
14h10 - CO-014 - Risk of skin ulcer and use of bisphosphonates: a national cohort study in the French healthcare database	C. Jambon-Barbara
14h20 - CO-015 - Visualization and presentation of drug utilization study results: going digital. The example of the Benzo'Viz DRUGS-SAFER digitalized interactive study report	A. Pariente
14h30 - CO-016 - Distinguishing between indications for use of medications in administrative data sources. Application to pregabalin and gabapentin. A contribution from the ConcePTION project	A.-B. Beau
14h40 - CO-017 - Evaluation of STOPP/START alerts for psychotropic drugs by general practitioners in the TAPAGE trial (EAT in English) in polymedicated patients aged 75 years and more	A. Elhousseiny Shaaban
14h50 - CO-018 - Compliance of oral isotretinoin use with prescription and delivery guidelines between 2014 and 2021 in France.	C. Bouvard

**15h00 - 16h30**

**Hall d'accueil**

**Pause café & visite des stands**

15h00 - 16h30		Zone jaune
<b>Posters Modérés (PM1) - Zone jaune - Session translationnelle - Oncopharmacologie</b>		
Modérateurs : Paul GOUGIS (Paris), Laurent BERTOLETTI (Saint-Etienne)		
PM1-001 - Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors		<b>P. Palassin</b>
PM1-002 - Venetoclax exposure-safety relationships in real life Acute Myeloïd Leukemia (AML) patients		<b>F. Puisset</b>
PM1-003 - Glucarpidase rescue in patients with delayed methotrexate clearance: is there a clinical benefit?		<b>S. Pierre</b>
PM1-004 - Pharmacovigilance contribution in a onco-cardio-pharmacology multidisciplinary team meeting		<b>M. Sassier</b>
PM1-005 - STK11/LKB1 mutation in non-small cell lung cancer: prognostic or predictive?		<b>P. Rosellini</b>
PM1-006 - Ex vivo histoculture drug response assay to uncover therapeutic opportunities in NRASQ61 mutated melanoma.		<b>C. Reger De Moura</b>
PM1-007 - Pharmacogenetic effects on 5-fluorouracil therapy in cancer patients		<b>A. Omezzine</b>

15h00 - 16h30		Zone verte
<b>Posters Modérés (PM1) - Zone verte - Pharmacologie clinique &amp; Méthodologie</b>		
Modérateur : Béranger LARGEAU (Tours), Matthieu ROUSTIT (Grenoble)		
PM1-008 - Impact of different bDMARDs on Patient Reported Outcomes in axial spondyloarthritis: a systematic review of the literature and meta-analysis.		<b>E. Gadon</b>
PM1-009 - Quality of Adverse Events Reporting in Clinical Trials of Covid-19 Drugs: a systematic review		<b>F. Montastruc</b>
PM1-010 - Breath metabolomics to monitor the response to the CFTR modulator triple combination therapy in adults with cystic fibrosis.		<b>E. Bardin</b>
PM1-011 - Modeling the effect of anesthetic drugs on the brain: a proof a concept		<b>M. Breyton</b>
PM1-012 - Evaluation of the medical cannabis clinical trials over the past ten years		<b>M. Laune</b>
PM1-013 - Regrouping of adverse events to better present safety data in statistical report		<b>C. Poncet</b>
PM1-014 - Simulation of within-subject variance of exposure differences in bioequivalence studies		<b>P. Lechat</b>
PM1-015 - Non-supervised machine learning for signal detection in pharmacovigilance: application to Oxford-AstraZeneca's COVID-19 vaccine		<b>F. Montastruc</b>

15h00 - 16h30		Zone rose
<b>Posters Modérés (PM1) - Zone rose - Personnalisation des traitements (session 1)</b>		
Modérateurs : Youssef BENNIS (Amiens), Marie-Clémence VERDIER (Rennes)		
PM1-016 - Determination of probability of target attainment, based on a tacrolimus twice a day modelling in adult heart transplant patient using the through concentration and the area under the curve		<b>A. Destere</b>
PM1-017 - Cefepime overexposure despite the use of recommended doses, a retrospective study in orthopedic surgery		<b>N.-H. Truong</b>
PM1-018 - Defining standard and high dosages for beta-lactams administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study		<b>S. Goutelle</b>
PM1-019 - A biological pharmacology network to secure the risk of drug-drug interaction with nirmatrelvir/ritonavir		<b>F. Lemaitre</b>
PM1-020 - Dalbavancin plasma concentrations in 133 patients: a PK-PD observational study		<b>M. Gregoire</b>
PM1-021 - Determination of the clindamycin dose to be administered by continuous infusion during combination therapy with rifampicin : a prospective population pharmacokinetics study.		<b>L. Mimram</b>



PM1-022 - Nirmatrelvir/ritonavir: efficacy, safety and drug monitoring in a real-life cohort of outpatient liver transplant recipients **C. Tron**

PM1-023 - Fifteen-year large-scale retrospective analysis of mycophenolate mofetil Bayesian dose adjustment in adult liver transplant recipients **C. Monchaud**

## 15h00 - 16h30

## Zone grise

### Posters Modérés (PM1) - Zone grise - Pharmacovigilance (session 1)

Modératrices : Aurélie GRANDVUILLEMIN (Dijon), Annie-Pierre JONVILLE-BERA (Tours)

PM1-025 - Kidney function decline and serious adverse drug reactions in patients with chronic kidney disease **V. Gras-Champel**

PM1-026 - Drug-induced membranous nephropathy: disproportionality analysis of the WHO safety database **A.-O. Gérard**

PM1-027 - Mianserin-induced sexual behaviour disorders: a case series **H. Richard**

PM1-028 - Fibroadenoma of the breast: an underappreciated adverse drug reaction of cyclosporin **J. Béné**

PM1-029 - Ruxolitinib and risk of non-Hodgkin's lymphoma **S. Bergeron**

PM1-030 - Adverse drug reaction profile of drug interactions involving a protein kinase inhibitor indicated in chronic myeloid leukemia from pharmacovigilance databases. **F. Despas**

PM1-031 - Patch tests and cross-reactivity among antiepileptic drugs **P. Sanchez-Pena**

PM1-024 - Comprehensive description of adult-onset Still's disease after COVID-19 vaccination **P. Palassin**

## 15h00 - 16h30

## Zone bleue

### Posters Modérés (PM1) - Zone bleue - Session translationnelle - Pharmacologie cardiovasculaire

Modérateurs : Jérémy BELLIEEN (Rouen), Véronique LEBLAIS (Paris)

PM1-032 - Effect of conditional deletion of endothelial Brain-derived Neurotrophic Factor on cardiovascular function **P. Totoson**

PM1-033 - Affinity of the active metabolite of prasugrel for arachidonic acid-rich platelet plasma membrane clusters that promote P2Y12 oligomerization **F. Allemand**

PM1-034 - Assessment of digital perfusion as a surrogate outcome in Raynaud's Phenomenon clinical trials **C. Khouri**

PM1-035 - CFTR modulator triple combination treatment modifies exhaled breath of children with cystic fibrosis within a week. **E. Bardin**

PM1-036 - Synthetic data and machine learning to predict the glomerular filtration rate in acute circulatory failure patients based on mRNA biomarkers **J.-B. Woillard**

PM1-037 - Valvular heart disease reporting and the use of methylphenidate : is there any difference between children and adults? **L. Chouchana**

PM1-038 - Diuretic dose is a strong prognostic factor in ambulatory patients awaiting heart transplantation **G. Baudry**

PM1-039 - Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors **A. Hlavaty**

## 15h00 - 16h30

## Appli mobile

### Posters simples (PS)

Retrouvez tous les posters simples (PS) téléchargeables au format PDF dans l'appli mobile du congrès!

## 16h30 - 18h00

## Amphi 400 A

### Méthodologie en recherche clinique et pharmaco-épidémiologie

Modérateurs : Silvy LAPORTE (Saint-Etienne), Julien BEZIN (Bordeaux)	
Conférence invitée 16h30 Emulated trials from real-world data for comparative effectiveness research - Clémence LEYRAT (Londres)	
Communications libres	
17h00 - CO-019 - Ordinal scales of clinical status and viral load as surrogates of mortality and disease worsening in COVID-19: an aggregate data meta-analysis	<b>G. Grenet</b>
17h10 - CO-020 - Impact of Covid-19 vaccination on pharmacovigilance spontaneous reporting in France	<b>S. De-Germay</b>
17h20 - CO-021 - The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study	<b>F. Naudet</b>
17h30 - CO-022 - Publication of randomized controlled trials with negative results in high impact medical journals increased between 2000 and 2020	<b>B. Laviolle</b>
17h40 - CO-023 - Influence of spin in abstracts on medical students' interpretation of the results: a randomized study.	<b>M. Roustit</b>
17h50 - CO-024 - Drug clustering through adverse reactions signature to anticipate new and unidentified aspects of drug safety profile: application to gabapentinoids and other voltage-gated calcium channel drug ligands	<b>B. Largeau</b>

### 16h30 - 18h00

### Amphi 400 B

#### STP

Modérateurs : Nicolas PICARD (Limoges), Françoise GOIRAND (Dijon)

Conférence invitée  
16h30 Clinical Pharmacogenomics Implementation in Thailand : A Dream come true - Chonlaphat SUKASEM (Thaïlande)

Communications libres

17h00 - CO-025 - Area under the curve of tacrolimus using microsampling devices: towards precision medicine in solid organ transplantation?	<b>F. Lemaitre</b>
17h10 - CO-026 - Optimization of beta-lactam antibiotics exposure in pediatric intensive care unit: protocolization of continuous infusion	<b>G. Ragonnet</b>
17h20 - CO-027 - Fluconazole resistant urinary candidiasis: Can voriconazole be used as an alternative treatment?	<b>C. Boglione-Kerrien</b>
17h30 - CO-028 - Variability of corticosteroids response in the treatment of chronic inflammatory bowel disease	<b>S. Boujaafar</b>
17h40 - CO-029 - Experience with Nirmatrelvir/ritonavir TDM in real life settings	<b>J. Guyon</b>
17h50 - CO-030 - Quantitative prediction of intravenous drug-drug interactions mediated by cytochrome P450 perpetrators	<b>V. Tuloup</b>

### 16h30 - 18h00

### Amphi 400 C

#### Session translationnelle #3 : Neuropsychopharmacologie

Modérateurs : Louise CARTON (Lille), Edouard LAFORGUE (Nantes)

Conférence invitée  
16h30 Dépression : les promesses et limites de la kétamine - Alain GARDIER (Paris)

Communications libres

17h00 - CO-034 - Reporting of Harms in Clinical Trials of Esketamine in Depression: A Systematic Review	<b>T. Taillefer De Laportalière</b>
17h10 - CO-031 - A significant proportion of methadone adverse effects are due to failure to take into account its pharmacological properties	<b>T. Soeiro</b>
17h20 - CO-032 - Association between clozapine plasma level and clinical outcomes - a first systematic review, meta-analysis and individual participant data meta-analysis	<b>Z. Djerada</b>
17h30 - CO-033 - Blockade of CCK2R prevents the onset of vincristine-induced sensory neuropathy in mice	<b>C. Demiot</b>
17h40 - CO-035 - Metabolomic profiles of 38 acylcarnitines in major depressive episodes before and after treatment: results from the METADAP and VARIETE cohorts	<b>A.-E.-K. Ait Tayeb</b>
17h50 - CO-036 - Impact of BTK inhibitor ibrutinib on chronic kidney disease-induced cognitive impairment in rats	<b>G. Hache</b>

**18h00 - 19h00**

**Amphi 400 A**

Réunion CNET

**18h00 - 19h00**

**Amphi 400 C**

Réunion CNPM

**18h00 - 19h00**

**Salle 309**

Réunion AEPFP

**19h00 - 20h30**

**Hall d'accueil**

Cocktail de bienvenue



**MARDI 13 JUIN**

08h00 - 09h30

Amphi C. Lombois  
(A600)

### Addictovigilance

Modératrices : Maryse LAPEYRE-MESTRE (Toulouse), Emilie BOUQUET (Poitiers)

Conférence invitée

08h00 Réduction des risques dans la dépendance au crack - Florence VORSPAN (Paris)

Communications libres

08h30 - CO-037 - 3-MMC's prohibition in the Netherlands, butterfly effect in France

A. Aquizerate

08h40 - CO-038 - Ten years of drug-related deaths in France: the DRAMES survey

B. Revol

08h50 - CO-039 - Cathinones consumption in France: overview of other New Psychoactive Substances (NPS) sold as 3-MMC since its ban in Netherlands (October 2021) and complications

E. Frauger

09h00 - CO-040 - Prevalence of ketamine detection in oral fluid of drivers in eastern France from 2020 to 2021

N. Gambier

09h10 - CO-041 - Could psychostimulant use among university students be related to attention disorder? Results of the PETRA study

C. Caron

09h20 - CO-042 - Medical prescription falsified by the patients: Analysis of the data recorded in the OSIAP Programme in 2021

E. Jouanjus

08h00 - 09h30

Amphi 400 A

### Actualités sur le médicament et actualités thérapeutiques

Modérateurs : Béatrice SAINT-SALVI (Paris), Philippe BERTIN (Limoges)

Conférence invitée

08h00 Les gliflozines - Béatrice DULY-BOUHANICK (Toulouse)

Communications libres

08h30 - ACT-001 - New JAK inhibitor safety data in 2023

P. Vergne Salle

08h40 - ACT-002 - Buprenorphine, the treatment of major opiate dependence today in injectable form: 25 years of galenic evolution

C. Victorri-Vigneau

08h50 - ACT-003 - Jak inhibitors in inflammatory dermatosis

L. Le Cleach

09h00 - ACT-004 - Population designations in pharmacological research: Limitations and perspectives

J.-C. Lega

09h10 - ACT-005 - Place of the new beta-lactams in Gram-negative bacterial infections in the ICU: a consensus conference of the Société de Réanimation de Langue Française (SRLF).

P.-F. Dequin

09h20 - ACT-006 - Zombie trials and the dark future of pharmachaology

F. Naudet

08h30 - 09h30

Amphi 400 B

### Pharmacologie des populations particulières

Modérateurs : Hélène GENIAUX (Limoges), Florian LEMAITRE (Rennes)

Communications libres

08h30 - CO-043 - Compliance with the pregnancy prevention program among women aged 11 to 50 years who initiated oral isotretinoin therapy

A. Havet

08h40 - CO-044 - COVACPREG: A French prospective cohort of pregnant women vaccinated against Covid-19

I. Lacroix

08h50 - CO-045 - Beta-blockers and breastfeeding: a real-life prospective study

R. Freppel

09h00 - CO-046 - Association study between clinical factors, CYP2D6 genetic polymorphisms and weight gain after antipsychotic treatment in pediatric patients: results from the ETAPE cohort

A.-E.-K. Ait Tayeb

09h10 - CO-047 - Bariatric surgery related impact on the efficacy and risks of oral drug: about 70 cases in the French Pharmacovigilance Database

S. Bergeron

09h20 - CO-048 - Pediatric medications containing alcohol in France

J. Perino

09h30 - 10h00

Amphi C. Lombois  
(A600)**Ma thèse en 180 secondes & Prix de M2**

Modérateurs : Luc ZIMMER (Lyon), Françoise STANKE-LABESQUE (Grenoble)

09h30 - TH-002 - Target-mediated drug disposition of monoclonal antibodies: a pharmacokinetic modelling study

O. Le Tilly

09h35 - TH-003 - Factors in the misuse of psychotropic treatments: from non-compliant prescriptions to inappropriate uses

E.-J. Laforgue

09h40 - TH-004 - Acute decompensation: what are the effects of blocking or neutralising vasopressin?

Y. Stephan

09h45 - TH-005 - Innovative therapeutic strategies in BRAF-mutated metastatic melanoma: Clinical evaluation of the anti-BRAF + anti-CDK4/6 combination and validation of Kindlin-3 as a new relevant target

B. Louveau

09h50 - M2-001 - Risk of skin ulcers and COX-2 inhibitors: a national population-based case-crossover study

C. Bernardeau

10h00 - 11h00

Hall d'accueil

**Pause café & visite des stands**

10h00 - 11h00

Zone jaune

**Posters modérés (PM2) - Zone jaune - Pharmaco-épidémiologie**

Modérateurs : Charles DOLLADILLE (Caen), Marion ALLOUCHERY (Poitiers)

PM2-001 - Use of baclofen for the treatment of alcohol use disorders between 2014 and 2021 in France

A. Ardillon

PM2-002 - Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting

L. Grimaldi

PM2-003 - Prescription of medication for the respiratory system in children aged 0-10 years: a longitudinal drug utilization study in the POMME database

J. Benevent

PM2-005 - Impact of COVID-19 pandemic on outpatient antibiotics use in France: a time-series analysis using nationwide data

N. Rousselot

PM2-006 - Risk of skin ulcers and COX-2 inhibitors: a national population-based case-crossover study

C. Bernardeau

10h00 - 11h00

Zone rose

**Posters modérés (PM2) - Zone rose - Personnalisation des traitements (session 2)**

Modérateurs : Elodie GAUTIER-VEYRET (Grenoble), Stéphane BOUCHET (Bordeaux)

PM2-007 - Optimization of Rituximab Therapy in Primary Membranous Nephropathy with Artificial Intelligence

A. Destere

PM2-008 - Questionnaire about Therapeutic Drug Monitoring (TDM) of psychotropics for a panel of French psychiatrists

S. Couderc

PM2-009 - Pharmacogenetic analysis of CYP2D6 and CYP2C19: is it worth performing next-generation sequencing (NGS) for these two cytochrome P450 enzymes?

L. Boccelari

PM2-010 - Pharmacogenetics of interferon beta in multiple sclerosis

M.-R. Ganouni

PM2-011 - Rituximab pharmacokinetics is mediated by both target antigen and neonatal receptor (FcRn) expressing cells: a multi target-mediated drug disposition (TMDD) mechanistic model

D. Ternant

PM2-012 - Towards precision dosing in psychiatry: population pharmacokinetics meta modelling of clozapine and lithium

S. Benito

10h00 - 11h00

Zone grise

**Posters modérés (PM2) - Zone grise - Pharmacovigilance (session 2)**

Modérateurs : Valérie GRAS (Amiens), Jean-Luc FAILLIE (Montpellier)

PM2-013 - Flexibility and reactivity are the key words of the Network of the French Regional Pharmacovigilance Centres: illustration based on 3 safety signals identified during the covid19 vaccination campaign

**A. Grandvullemin**

PM2-014 - Robustness of safety signals generated by disproportionality analyses from spontaneous reporting systems: a meta-research study

**C. Khouri**

PM2-015 - Assessing the risk of adverse pregnancy outcomes and birth defects reporting in women exposed to ganciclovir or valganciclovir during pregnancy: a pharmacovigilance study

**L. Chouchana**

PM2-016 - Spontaneous report related to azithromycin throughout the COVID-19 pandemic in France: a pharmacovigilance study

**C. De Torcy**

PM2-017 - Cross reactivity among macrolides, lincosamides and streptogramins: a descriptive study on the french national pharmacovigilance database.

**Q. Le Baron**

PM2-018 - Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance data report

**K. Bihan****10h00 - 11h00****Zone verte****Posters modérés (PM2) - Zone verte - Addictovigilance**

Modératrices : Hélène PEYRIERE (Montpellier), Aurélie AQUIZERATE (Nantes)

PM2-019 - Psychoactive substances : Back to nature

**E. Laforgue**

PM2-020 - Methylphenidate misuse: Assessment in Occitanie-East between 2018 and 2022

**H. Peyriere**

PM2-021 - Addictovigilance follow-up of medical cannabis during the French Experimentation

**C. Chevallier**

PM2-022 - Intravenous injection of oral morphine: users in favor of an injectable substitution

**C. Bertin**

PM2-023 - Use of psychoactive substances among university students

**J. Tournebize****10h00 - 11h00****Zone bleue****Posters modérés (PM2) - Zone bleue - Session translationnelle - Neuropsychopharmacologie**

Modératrices : Julie DEGUIL (Lille), Claire DEMIOT (Limoges)

PM2-024 - Development and validation of a LC-MS/MS method for the quantitation of 21 anti-epileptic drugs in saliva

**C. Almeida**

PM2-025 - Assessment of the psychedelic 5-MeO-DMT for anxiolytic and antidepressant-like effects

**R. Hacquet**

PM2-026 - The neuropsychiatric safety profile of lasmiditan: comparative disproportionality analysis with triptans

**D. Merino**

PM2-027 - Methylphenidate prescription in adult attention deficit disorder with or without hyperactivity (ADHD) – a pharmacovigilance study

**C. Salvez**

PM2-028 - Risk of respiratory depression and death related with concomitant use of opioids and gabapentinoids : a systematic review

**M. Lapeyre-Mestre**

PM2-029 - Vaccines and the risk of Guillain-Barre Syndrome, analysis of the French pharmacovigilance database

**M. Gligorov****10h00 - 11h00****Zone violette****Posters modérés (PM2) - Zone violette - Modèles pharmacocinétiques in vitro et in silico**

Modérateurs : Matthieu GREGOIRE (Nantes), Zoubir DJERADA (Reims)

PM2-030 - Negative impact of STEMI and morphine dose on ticagrelor uptake and effect: a population PK-PD analysis of pooled individual participant data

**C. Konecki**

PM2-031 - In-vitro tacrolimus penetration in lymphocytes and its impact on T-cells functional assessment by ELISpot-IFN?

**T. Jouve**

PM2-032 - Model-informed precision dosing of high-dose IV busulfan in Thai pediatric patients	<b>F. Thomas</b>
PM2-033 - Pharmacological insights into structure and dynamics of membrane transporters by means of molecular dynamics simulations: OAT1 and MRP1 case studies	<b>F. Di Meo</b>
PM2-034 - Linezolid concentration-toxicity relationship: looking back on ten years of therapeutic drug monitoring	<b>S. Lalanne</b>
PM2-035 - Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses	<b>C. Konecki</b>

**10h00 - 11h00**

**Appli mobile**

**Posters simples (PS)**

Retrouvez tous les posters simples (PS) téléchargeables au format PDF dans l'appli mobile du congrès!

**11h00 - 12h30**

**Amphi 400 A**

**Table ronde : élaboration des recommandations**

Modérateurs : Clara LOCHER (Rennes), Jean-Christophe LEGA (Lyon)

**Intervenants**

Le point de vue du pharmacologue dans l'élaboration des recommandations - Patrick MISMETTI (CHU - Saint-Etienne)

Comment élaborer des référentiels de société savante : l'exemple de la Société Française d'Anesthésie-Réanimation (SFAR) - Marc GARNIER (Clermont-Ferrand)

Les recommandations de bonne pratique de la HAS - Pierre GABACH (HAS - Paris)

**11h00 - 12h30**

**Amphi 400 B**

**STP - Modélisation**

Modérateurs : Jean-Baptiste WOILLARD (Limoges), Françoise STANKE-LABESQUE (Grenoble)

**Conférence invitée**

11h00 Integrative kinetics and machine learning modeling for prediction of outcome following immunotherapy in lung cancer - Sébastien BENZEKRY (Marseille)

**Communications libres**

11h30 - CO-049 - Development of a dosing algorithm integrating pharmacogenetic markers and inflammation for individualization of initial voriconazole doses

**E. Gautier-Veyret**

11h40 - CO-050 - The ExpoTac study: association between adverse events and tacrolimus exposure after renal transplantation.

**C. Monchaud**

11h50 - CO-051 - PKPD relationship of Ipilimumab plus Nivolumab combination in patients with advanced melanoma

**L. Goldwirt**

12h00 - CO-052 - Development of a a priori tool to determine the frequency of dalbavancin administrations using a population pharmacokinetic approach

**M. Gregoire**

12h10 - CO-053 - Development and validation of a dosing nomogram for continuous infusion cloxacillin in infective endocarditis

**R. Bellouard**

12h20 - CO-054 - Pharmacokinetics-Pharmacodynamic study of subcutaneous infusion of daptomycin in healthy volunteers.

**M.-C. Verdier**

**12h30 - 14h00**

**Hall d'accueil**

**Déjeuner et visite des stands**

**13h00 - 14h00**

**Amphi 400 A**



## Symposium partenaire Galapagos - Guide PRACtue des JAKi

Les JAKi, une nouvelle classe thérapeutique : positionnement, encadrement PRAC et tolérance - Pr Bertin, rhumatologue, CHU de Limoges

Pharmacodynamique et sélectivité de la classe des JAK : que sait-on aujourd'hui ? - Rene Galien, Galapagos (à distance)

Regard croisé rhumato/gastro : JAKi, au-delà de l'inflammation - Pr Vergne-Salle et Dr Geyl, rhumatologue et gastroentérologue, CHU de Limoges

Questions / Réponses

13h00 - 14h00

Amphi 400 B

### Symposium partenaire Thermo Fisher : Soyez prêts pour vos analyses pharmacogénétiques !

1.Pr Nicolas Picard : Un passeport pharmacogénétique pour sécuriser la prescription et la dispensation des médicaments : les résultats de l'étude Européenne PREPARE  
2.Dr. Charity Nofziger, Pharmacogenetic Analytics: Laboratory versus CYP2D6

Chairman : Pr Nicolas Picard et Mme Dewolf Dominique

14h00 - 15h30

Amphi C. Lombois (A600)

### Thème transversal - partie 1 : Transplantation

Modérateurs : Florian LEMAITRE (Rennes), Jean-Baptiste WOILLARD (Limoges)

Conférences invitées

14h00 Pharmacologie de la transplantation - Pierre MARQUET (Limoges)

14h30 Microbiote et transplantation: contribution du microbiote digestif à l'immunomodulation et au métabolisme des immunosuppresseurs - Roland LAWSON (Limoges)

15h00 Biomarqueurs pharmacodynamiques en transplantation - Dany ANGLICHEAU (Paris)

15h30 - 16h00

Hall d'accueil

Pause-café & visite des stands

16h00 - 17h30

Amphi C. Lombois (A600)

### Thème transversal - partie 2 : Transplantation

Modérateurs : Dany ANGLICHEAU (Paris), Pierre MARQUET (Limoges)

Conférences invitées

16h00 Pharmacologie & innovation thérapeutique dans la pratique clinique de la transplantation rénale - Thomas JOUVE (Grenoble)

16h30 Approches pharmacologiques de la préservation d'organes explantés - Raphaël THUILLIER (Poitiers)

17h00 Application de l'intelligence artificielle en pharmaco et transplantation - Jean-Baptiste WOILLARD (Limoges)

17h30 - 18h00

Amphi C. Lombois (A600)

Assemblée générale du syndicat des pharmacologues (SYNAPS)

20h00 - 23h30

Restaurant Le Lanaud

Soirée du congrès (sur inscription)



**MERCREDI 14 JUIN**

09h00 - 10h30

Amphi C. Lombois  
(A600)

## Pharmacovigilance

Modérateurs : Thierry VIAL (Lyon), Ghada MIREMONT (Bordeaux)

Conférence invitée

09h00 Sécurité des médicaments chez les sujets âgés : quelles actualités ? - Marie-Laure LAROCHE (Limoges)

Communications orales

09h30 - CO-055 - Severe cutaneous adverse reactions (SCARs) induced by iodinated contrast media (ICM) : study of French pharmacovigilance database

G. Veyrac

09h40 - CO-056 - Comparative semiology of drug-induced uveitis related to Checkpoint inhibitors and MAP-kinase pathway inhibitors

T. Thibault

09h50 - CO-057 - Rotavirus vaccine safety profile: a 15-year post-marketing surveillance in France

A.-P. Jonville-Bera

10h00 - CO-058 - Drug-induced minimal change disease: disproportionality analysis of the WHO safety database

A.-O. Gérard

10h10 - CO-059 - Medication error in ambulatory care

J. Mahé

10h20 - CO-060 - The Reporting of A Disproportionality analysis for drUg Safety signal detection using spontaneously reported adverse events in Pharmacovigilance (READUS-PV)

C. Khouri

09h00 - 10h30

Amphi 400 A

## Table ronde - Actualité : Hydroxychloroquine et Covid : fin de partie !

- Historique des essais et communication de la SFPT - Matthieu ROUSTIT (Grenoble)
- Données de pharmacovigilance - Milou-Daniel DRICI (Nice)
- Estimation de la surmortalité liée à l'usage compassionnel de l'hydroxychloroquine - Jean-Christophe LEGA (Lyon)
- La position des sociétés savantes : histoire d'une tribune - Mathieu MOLIMARD (Bordeaux)
- Therapies : engagement d'une revue pour le respect de l'Evidence Based-Medicine - Dominique DEPLANQUE (Lille)

09h00 - 10h30

Amphi 400 B

## Session R&D / Innovation : Innovations technologiques pour la pharmacologie

Modérateurs : Yves FROMES (Paris), Chantal KREZEL (Paris)

Intervenants

La résonance paramagnétique électronique (RPE) : principe et applications en biologie - Fabienne PEYROT (Paris)

L'imagerie au service des essais cliniques - Isabelle ACKERMANN-BONAN (Paris)

De la mort du criblage virtuel à la navigation dans des espaces chimiques ultra-larges - Didier ROGNAN (Strasbourg)

10h30 - 11h00

Hall d'accueil

Pause-café & visite des stands

11h00 - 12h00

Amphi C. Lombois  
(A600)

Assemblée Générale de la SFPT et remise des prix

12h00 - 13h00

Hall d'accueil

Déjeuner et visite des stands

13h00 - 16h00

Amphi C. Lombois  
(A600)

Atelier Expérimentation animale : Gros animaux

Formateurs : Claude COUQUET & Florence BOSSELUT (Limoges)

13h00 - 16h00

Amphi 400 A

Atelier DPC - 65952325001 Bon usage des médicaments : comment bien réaliser une déprescription ?

Intervenantes :


Pr Marie-Laure Laroche, CHU Limoges, France

Pr Caroline Sirois, Université Laval, Canada (à distance)


Pr Anne Spinewine, UC Louvain, Belgique (à distance)

Dr Anne Niquille, UnisSanté Lausanne, Suisse



# Niveau 0 (RDC Haut)




# Niveau 0 (RDC bas)



# Niveau 2



Ascenseur  
Vers niveau 3  
(salles 301, 308, 309)




Toilettes

- Vers Hall d'accueil / Sortie (niveau 0 - RDC haut)
- Vers amphi C. Lombois (A600) + posters modérés zones rose, bleue, grise et jaune (niveau 0 - RDC bas)




Posters modérés  
Zone verte

Posters modérés  
Zone violette




Entrée

Amphi 400 A



Entrée

Amphi 400 B




Entrée

Amphi 400 C



# Niveau 3



# REMERCIEMENTS

LA SFPT REMERCIE SES PARTENAIRES POUR L'INTÉRÊT  
ET LE SOUTIEN QU'ILS ONT APPORTÉS À CE CONGRÈS.



Galápagos



AMARIN

Lilly

**Inserm**  
La science pour la santé  
From science to health

N° 6595  
**odpc**  
Organisme enregistré par l'Agence nationale du DPC  
Retrouvez toute l'offre du DPC sur [www.odpc.fr](http://www.odpc.fr)



**RDV à Tours pour l'édition 2024 ! 18 > 20 juin**